Pyxis Oncology
PYXS
31 hedge funds and large institutions have $26.5M invested in Pyxis Oncology in 2022 Q4 according to their latest regulatory filings, with 2 funds opening new positions, 13 increasing their positions, 6 reducing their positions, and 9 closing their positions.
117% more repeat investments, than reductions
Existing positions increased: 13 | Existing positions reduced: 6
2.91% less ownership
Funds ownership: 59.21% → 56.3% (-2.9%)
18% less funds holding
Funds holding: 38 → 31 (-7)
28% less capital invested
Capital invested by funds: $36.6M → $26.5M (-$10.2M)
78% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 9
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TCM
Tang Capital Management
San Diego,
California
|
+$3.09M |
| 2 |
NM
Newtyn Management
New York
|
+$1.05M |
| 3 |
MAM
Marquette Asset Management
Minneapolis,
Minnesota
|
+$88.3K |
| 4 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$75K |
| 5 |
Acadian Asset Management
Boston,
Massachusetts
|
+$71.8K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PA
Perceptive Advisors
New York
|
-$3.01M |
| 2 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$1.51M |
| 3 |
LGM
Logos Global Management
San Francisco,
California
|
-$434K |
| 4 |
CS
Credit Suisse
Zurich,
Switzerland
|
-$299K |
| 5 |
Millennium Management
New York
|
-$87.8K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
Northern Trust
Chicago,
Illinois
| $35.4K | – | – | – |
|
27
Deutsche Bank
Frankfurt Am Main Ge,
Germany
| $33.5K | – | – | – |
|
28
Charles Schwab
San Francisco,
California
| $23.8K | – | – | – |
|
29
Tudor Investment Corp
Stamford,
Connecticut
| $18K | – | – | – |
|
|
TRCT
30
Tower Research Capital (TRC)
New York
| $8K | -$14.3K | -9,558 | -61% |
|
31
Wells Fargo
San Francisco,
California
| $214 | +$21 | +14 | +10% |
|
|
PA
32
Perceptive Advisors
New York
| – | -$3.01M | -1,528,812 | Closed |
|
|
RCM
33
RA Capital Management
Boston,
Massachusetts
| – | -$1.51M | -764,653 | Closed |
|
|
LGM
34
Logos Global Management
San Francisco,
California
| – | -$434K | -220,434 | Closed |
|
|
CS
35
Credit Suisse
Zurich,
Switzerland
| – | -$299K | -152,018 | Closed |
|
|
PCM
36
Prelude Capital Management
New York
| – | -$22K | -11,052 | Closed |
|
37
Two Sigma Advisers
New York
| – | -$20K | -10,400 | Closed |
|
38
Fidelity Investments
Boston,
Massachusetts
| – | -$2K | -855 | Closed |
|
PYXS Hedge Fund Activity: Q4 2022 in Review
31 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in Pyxis Oncology (PYXS) for Q4 2022, worth a combined $26.5M — down 28% from $36.6M a quarter earlier.
Sellers outnumbered buyers: 9 funds closed out of PYXS and 2 opened new positions — a net loss of 7 holders — while 6 trimmed existing stakes and 13 added.
The largest buyer was Tang Capital Management, adding an estimated $3.09M. The largest seller was Perceptive Advisors, exiting entirely with an estimated $3.01M sold.
- 31 institutional investors held Pyxis Oncology (PYXS) as of Q4 2022, down from 38 in Q3 2022.
- Funds reported $26.5M of Pyxis Oncology stock for Q4 2022, down 28% quarter-over-quarter.
- 2 funds opened new Pyxis Oncology positions in Q4 2022 and 9 closed out, a net change of -7 holders.
- The largest Pyxis Oncology buyer in Q4 2022 was Tang Capital Management, an estimated $3.09M added.
- The largest Pyxis Oncology seller in Q4 2022 was Perceptive Advisors, an estimated $3.01M sold.
Based on aggregated 13F filings for Q4 2022.